iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

Core Insights - iBio, Inc. has announced promising preclinical data for its Activin E antibody, showing a 26% reduction in fat mass in diet-induced obese mice while preserving muscle mass [1][6] - The study indicates that fat-specific weight loss is a higher-quality form of weight loss, reducing risks associated with heart and metabolic diseases [2][3] - The Activin E antibody demonstrated significant reductions in specific fat depots, with a 31% reduction in subcutaneous fat and reductions of 34% and 37% in epididymal and retroperitoneal fat, respectively [3][6] - When combined with a GLP-1 receptor agonist, the Activin E antibody resulted in a total fat mass reduction of 77%, with subcutaneous fat loss increasing to 74% [3][6] Company Overview - iBio, Inc. is a biotech company focused on developing next-generation biopharmaceuticals for cardiometabolic diseases, obesity, and cancer using AI and advanced computational biology [4] - The company aims to transform drug discovery and accelerate development timelines to address significant unmet medical needs in precision medicine [4]